Insider Selling: Athira Pharma (NASDAQ:ATHA) Insider Sells 1,644 Shares of Stock

Athira Pharma, Inc. (NASDAQ:ATHA) insider Martin Javier San sold 1,644 shares of the firm’s stock in a transaction dated Friday, January 2nd. The stock was sold at an average price of $6.88, for a total value of $11,310.72. Following the transaction, the insider owned 10,189 shares of the company’s stock, valued at $70,100.32. This trade represents a 13.89% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Athira Pharma Trading Down 5.5%

ATHA stock traded down $0.38 during trading on Monday, hitting $6.58. The company had a trading volume of 163,152 shares, compared to its average volume of 3,184,091. The stock has a market cap of $25.93 million, a PE ratio of -0.68 and a beta of 2.79. The business has a 50-day moving average of $5.03 and a 200-day moving average of $4.27. Athira Pharma, Inc. has a one year low of $2.20 and a one year high of $8.36.

Athira Pharma (NASDAQ:ATHA) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($1.68) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.17) by ($1.51). Research analysts forecast that Athira Pharma, Inc. will post -2.35 EPS for the current year.

Institutional Investors Weigh In On Athira Pharma

A hedge fund recently bought a new stake in Athira Pharma stock. Focus Partners Wealth bought a new position in shares of Athira Pharma, Inc. (NASDAQ:ATHA) during the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor bought 8,415 shares of the company’s stock, valued at approximately $35,000. Focus Partners Wealth owned 0.21% of Athira Pharma as of its most recent SEC filing. Institutional investors and hedge funds own 57.12% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Athira Pharma in a research report on Wednesday, October 8th. Mizuho set a $4.00 target price on Athira Pharma in a report on Friday, September 19th. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the company currently has an average rating of “Sell” and a consensus target price of $4.00.

About Athira Pharma

Athira Pharma, Inc is a clinical?stage biopharmaceutical company headquartered in Seattle, Washington, that is dedicated to developing therapies aimed at restoring neuronal health and slowing the progression of neurodegenerative diseases. Founded in 2011, Athira’s research focuses on the Hepatocyte Growth Factor (HGF)/MET pathway as a novel mechanism to promote neuronal repair, synaptic function and overall cognitive performance. The company’s overarching goal is to offer disease?modifying treatments for conditions such as Alzheimer’s disease, Parkinson’s disease, Huntington’s disease and amyotrophic lateral sclerosis (ALS).

The centerpiece of Athira’s pipeline is fosgonimeton (ATH?1017), a small?molecule positive modulator of the HGF/MET system.